{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.3","upperLimit":"149","value":"73.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"description":"Overall survival defined as time from registration to disease progression or death from any cause.","dispersionType":"Full Range","groups":[{"description":"Imatinib mesylate 400 mg orally daily, HES participants start with 100 mg orally daily.","id":"OG000","title":"Imatinib Mesylate"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From the start of therapy to death or disease progression, assessed up to 12 years and 5 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}